602-02-8

Upstream product

• 602-03-9 2,3-dinitroaniline 

Downstream Products

• 860241-04-9 (2-chloro-6-nitrophenyl)(p-tolyl)sulfane 
• 59483-54-4 3-chloro-2-nitro-aniline 
• 769-11-9 2-chloro-6-nitroaniline 
• 70-34-8 2,4-Dinitrofluorobenzene 
• 3535-67-9 2,6-dinitroanisole 
• 16931-35-4 4-chloro-1H-1,3-benzodiazole 
• 71635-98-8 4-chloro-2-phenyl-1H-benzo[d]imidazole 
• 90352-49-1 (2-chloro-6-nitro-phenyl)-p-tolyl sulfone 
• 18523-14-3 1,3-dimethoxy-2,4-dinitro-benzene 
• 23789-10-8 5-chloro-4-methoxy-1,3-dinitrobenzene 
• 10250-71-2 3-chloro-2,6-dinitro-aniline 
• 3531-19-9 2-chloro-4,6-dinitroaniline 
• 32337-97-6 1-chloro-2-iodo-3-nitrobenzene 
• 103298-52-8 erythro-9-(2-hydroxy-3-nonyl)-1,3-dideazaadenine 

Relevant academic research and scientific papers

Skin patch for use in contact immunotherapy

A device, preferably in the form of a skin patch, is disclosed for usage in the delivery of a contactant to human skin for the purpose of treating medical conditions responsive to contact immunotherapy, without the presence of medication to alleviate contact dermatitis induced by the contactant. The skin patch specifically induces a cell-mediated contact dermatitis in the treatment of skin disorders. Its anticipated use pertains to treatment of, for example, human papilloma virus infections, or warts. In a first embodiment, a pressure activated single chambered skin patch is topically applied and used for controlled release of contactant to human skin. In a second embodiment, a pressure activated two-chambered skin patch is topically applied and used for controlled release of a contactant to human skin. Alternatively, a single chambered skin patch is topically applied and hydrated by the contacted skin for release of contactant. In an additional embodiment, the contactant may be applied separately of the skin patch portion, in a manner that maintains the contactant in contact with the patient's skin for the predetermined period of time necessary to cause sufficient contact dermatitis to effect resolution of the medical condition.

Adenosine Deaminase Inhibitors. Syntheis and Biological Activity of Deaza Analogues of erythro-9-(2-Hydroxy-3-nonyl)adenine

Two new deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA, 1), 7-deaza-EHNA (6) and 1,3-dodeaza-EHNA (11), were synthesized and evaluated for adenosine deaminase (ADA) inhibitory activity and compared with EHNA, 1-deaza-EHNA (2), and 3-deaza-E